MARKET

HGEN

HGEN

Humanigen Inc
NASDAQ
0.2019
+0.0239
+13.43%
After Hours: 0.1875 -0.0144 -7.13% 19:59 10/04 EDT
OPEN
0.2136
PREV CLOSE
0.1780
HIGH
0.2587
LOW
0.1830
VOLUME
77.05M
TURNOVER
0
52 WEEK HIGH
8.38
52 WEEK LOW
0.1451
MARKET CAP
20.93M
P/E (TTM)
-0.0840
1D
5D
1M
3M
1Y
5Y
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session
Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday.
Benzinga · 15h ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 37.7% to $15.85 during Tuesday's pre-market session. The company's market cap stands at $23.3 million.
Benzinga · 19h ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investor Place · 20h ago
Humanigen to Participate in H.C. Wainwright and Cantor Investor Conferences in September 2022
Short Hills, New Jersey--(Newsfile Corp. - September 7, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab ("LENZ®"), a first-in class antibody that neutralizes granulocyte-macr...
Newsfile · 09/07 10:55
Humanigen Chief Medical Officer Adrian Kilcoyne Resigns
Humanigen Chief Medical Officer Adrian Kilcoyne Resigns
MT Newswires · 09/02 16:35
Why Bed Bath & Beyond Jumped Around 25%; Here Are 68 Biggest Movers From Yesterday
Gainers
Benzinga · 08/30 09:23
12 Health Care Stocks Moving In Monday's Intraday Session
 
Benzinga · 08/29 17:41
Why Chimerix Is Trading Higher By Over 19%, Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers Advanced Human Imaging Limited (NASDAQ: AHI) shares jumped 53% to $1.04. Advanced Human Imaging announced Sunday it signed a Master Services Agreement with Estonia-based Activate Health OÜ.
Benzinga · 08/29 16:49
More
About HGEN
Humanigen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing its portfolio of Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Its Humaneered technology platform offers a method for converting existing antibodies into engineered human antibodies designed for therapeutic use, primarily with acute and chronic conditions. The Company’s lead product candidate, lenzilumab, and its other two product candidates, ifabotuzumab (iFab) and HGEN005, are Humaneered monoclonal antibodies. Its lenzilumab product is a monoclonal antibody that has been demonstrated to neutralize human granulocyte-macrophage colony-stimulating factor (GM-CSF). Its ifabotuzumab product is focused on the EphA3 receptor. Its HGEN005 product is selectively targeting the eosinophil receptor EMR1. Its subsidiaries include Humanigen, Ltd., Humanigen Australia Pty, Ltd. and Humanigen Europe, Ltd.

Webull offers kinds of Humanigen Inc stock information, including NASDAQ:HGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HGEN stock methods without spending real money on the virtual paper trading platform.